🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "huge turning point" in the battle against drug-resistant strains of the infection, according to health experts.

A Worldwide Challenge

The sexually transmitted infection are on the rise globally, with figures suggesting in excess of 82 million new cases annually. Notably increased rates are observed in Africa and nations within the WHO's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have reached a record high, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary development in the face of growing infection rates, escalating drug resistance and the very limited therapeutic options presently on offer.”

Public health authorities are deeply concerned about the rise in drug-resistant strains. The global health body has designated it as a "high-priority threat". Ongoing monitoring showed that the effectiveness of key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Receive Approval

Zoliflodacin, also known as Nuzolvence, was authorized by the American regulatory agency in mid-December for combating gonorrhoea. This infection can lead to significant complications, including infertility. Scientists hope that focused deployment of this new drug will help slow the spread of drug resistance.

Gepotidacin, created by the drugmaker GlaxoSmithKline, was also approved in concurrent days. This medication, which is additionally indicated for urinary tract infections, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment was the result of a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to see it through.

“This approval signifies a significant shift in the treatment of multidrug-resistant gonorrhoea, which previously has been outpacing antibiotic development.”

Research Study Outcomes and Worldwide Availability

According to results published in a major medical journal, the new drug eradicated over nine in ten of uncomplicated infections. This places it at an comparable level with the current standard treatment, which involves two antibiotics. The research included hundreds of patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, GARDP has the rights to register and commercialise the drug in many developing nations.

Medical professionals on the front lines have voiced hope. Access to a one-pill regimen like this is hailed as a "game-changer" for managing the epidemic. This is viewed as vital to lessen the impact of the disease for individuals and to prevent the spread of extremely resistant gonorrhoea globally.